鍏充簬<\/b> Octapharma<\/b><\/p> \n
Octapharma 鍏徃鎬婚儴浣嶄簬鐟炲+鎷変酣锛屾槸鍏ㄧ悆鏈€澶х殑浜虹被铔嬬櫧璐ㄧ敓浜у晢涔嬩竴锛屼富瑕佸紑鍙戝拰鐢熶骇婧愪簬浜虹被琛€娴嗗拰浜虹被缁嗚優绯荤殑浜虹被铔嬬櫧銆�<\/p> \n
Octapharma 鍦ㄥ叏鐞冩嫢鏈� 11,000 澶氬悕鍛樺伐锛岄€氳繃鍏嶇柅鐤楁硶銆佽娑插鍜岄噸鐥囩洃鎶や笁澶ф不鐤楅鍩熺殑浜у搧锛屼负 118 涓浗瀹禱/鍦板尯鐨勬偅鑰呮彁渚涙不鐤楁敮鎸併€�<\/p> \n
Octapharma 鍦ㄥゥ鍦板埄銆佹硶鍥姐€佸痉鍥藉拰鐟炲吀鎷ユ湁涓冧釜鐮斿彂鍩哄湴鍜屼簲涓厛杩涚敓浜ц鏂斤紝骞跺湪娆ф床鍜岀編鍥借绔� 190 澶氫釜琛€娴嗘崘璧犱腑蹇冦€侽ctapharma 鍦ㄦ偅鑰呮姢鐞嗘柟闈㈢Н绱簡 40 骞寸殑涓板瘜缁忛獙銆�<\/p> \n
鍏充簬<\/b> Nuwiq <\/b>®<\/sup><\/b><\/p> \n
Nuwiq®<\/sup> (simoctocog alfa) 鏄 4 浠i噸缁勫洜瀛� VIII (rFVIII) 铔嬬櫧锛屾簮鑷汉绫荤粏鑳炵郴锛屾湭缁忓寲瀛︿慨楗版垨涓庝换浣曞叾浠栬泲鐧借瀺鍚�1<\/sup>銆傚湪鍩瑰吇杩囩▼涓笉鍚汉婧愭€ф垨鍔ㄧ墿婧愭€ф坊鍔犲墏銆備笉鍚潪浜虹被铔嬬櫧鎶楀師琛ㄤ綅锛屼笌琛€绠℃€ц鍙嬬梾鍥犲瓙鍏锋湁楂樺害浜插拰鎬�1<\/sup>銆侼uwiq®<\/sup> 娌荤枟宸插湪涔濋」1-3<\/sup> 宸插畬鎴愮殑涓村簥璇曢獙涓繘琛屼簡璇勪及锛屽寘鎷� 201 鍚嶆帴鍙楄繃娌荤枟锛�190 浜猴級1<\/sup> 銆�108 鍚嶆湭鎺ュ彈杩囨不鐤�2<\/sup> 鐨勯噸鐥� A 鍨嬭鍙嬬梾鎮h€呫€侼uwiq®<\/sup> 鎻愪緵 250 IU銆�500 IU銆�1,000 IU銆�1,500 IU銆�2,000 IU銆�2,500 IU銆�3,000 IU 鍜� 4,000 IU 鍏瑙勬牸4<\/sup>銆侼uwiq® <\/sup>宸茶幏鍑嗙敤浜庢不鐤楀拰棰勯槻鍚勫勾榫勭粍 A 鍨嬭鍙嬬梾锛堝厛澶╂€� FVIII 缂轰箯锛夋偅鑰呯殑鍑鸿4<\/sup>銆� <\/p> \n
鍏充簬<\/b> wilate<\/b>®<\/sup><\/b><\/p> \n
wilate® <\/sup>鏄竴绉嶉珮绾害浜虹被琛€绠℃€ц鍙嬬梾鍥犲瓙\/鍑濊鍥犲瓙 VIII (VWF\/FVIII) 娴撶缉鍓傦紝鍦ㄧ敓浜ц繃绋嬩腑閲囩敤鍙岄噸鐥呮瘨鐏椿姝ラ5<\/sup>銆傛湭娣诲姞鐧借泲鐧戒綔涓虹ǔ瀹氬墏5<\/sup>銆傜粡杩囩函鍖栬繃绋嬶紝VWF 涓� FVIII 鐨勬瘮鐜囪揪鍒颁笌鏅€氳娴嗚繎浼肩殑 1:15<\/sup>銆倃ilate® <\/sup>鍚湁涓€绉� VWF 涓夐噸缁撴瀯浠ュ強涓庢櫘閫氫汉琛€娴嗙被浼肩殑澶у垎瀛愰噺澶氳仛浣撳惈閲�5<\/sup>銆倃ilate®<\/sup>鎻愪緵 500 IU 鍜� 1000 IU 涓ょ瑙勬牸銆�6<\/sup>wilate® <\/sup>鍦ㄤ粎浣跨敤鍘绘皑鍔犲帇绱� (DDAVP) 鏃犳晥鎴栧瓨鍦ㄤ娇鐢ㄧ蹇屾椂锛岀敤浜庨闃插拰娌荤枟琛€绠℃€ц鍙嬬梾 (VWD) 鎮h€呯殑澶у嚭琛€鎴栨墜鏈嚭琛€锛屽悓鏃惰繕鐢ㄤ簬娌荤枟鍜岄闃� A 鍨嬭鍙嬬梾锛堝厛澶╂€� FVIII 缂轰箯锛夋偅鑰呯殑鍑鸿6<\/sup>銆傜編鍥介闃叉€ф不鐤楃殑閫傚簲鐥囪瑙佹洿鏂板悗鐨勫鏂逛俊鎭細wilate 瀹屾暣澶勬柟淇℃伅 (wilateusa.com)<\/a><\/p> \n
Octapharma 鏂伴椈绋夸笓渚涘仴搴蜂笓瀹禱/鍖荤枟濯掍綋浣跨敤锛屼笉闈㈠悜娑堣垂鑰呭獟浣撱€� <\/p> \n
1. Lissitchkov T et al.鈥疶her Adv Hematol鈥�2019; 10:2040620719858471.<\/p> \n
2. Liesner RJ et al.Thromb Haemost 2021; 121:1400-8.<\/p> \n
3. Octapharma AG; Data on file.<\/p> \n
4. Nuwiq®<\/sup> Summary of Product Characteristics. <\/p> \n
5. Stadler M et al.鈥疊iologicals鈥�2006; 34:281-8.<\/p> \n
6. wilate®<\/sup> Summary of Product Characteristics. <\/p> \n
鑱旂郴鏂瑰紡锛�
Ivana Spotakova
+41 79 3474607
Ivana.Spotakova@octapharma.<\/a>com<\/a><\/p> \n